Your browser is no longer supported. Please, upgrade your browser.
Settings
RGNX REGENXBIO Inc. daily Stock Chart
RGNX [NASD]
REGENXBIO Inc.
Index- P/E19.39 EPS (ttm)2.26 Insider Own1.10% Shs Outstand36.86M Perf Week-2.88%
Market Cap1.62B Forward P/E- EPS next Y-3.33 Insider Trans-56.39% Shs Float30.44M Perf Month-4.65%
Income79.60M PEG9.69 EPS next Q-0.38 Inst Own81.70% Short Float7.82% Perf Quarter-27.68%
Sales179.80M P/S9.00 EPS this Y-2.70% Inst Trans0.11% Short Ratio4.80 Perf Half Y-41.56%
Book/sh14.54 P/B3.02 EPS next Y-225.70% ROA23.30% Target Price77.07 Perf Year44.14%
Cash/sh10.11 P/C4.34 EPS next 5Y2.00% ROE24.60% 52W Range23.25 - 85.10 Perf YTD4.62%
Dividend- P/FCF19.15 EPS past 5Y- ROI-41.50% 52W High-48.43% Beta0.44
Dividend %- Quick Ratio20.20 Sales past 5Y- Gross Margin96.40% 52W Low88.77% ATR3.25
Employees139 Current Ratio20.20 Sales Q/Q307.70% Oper. Margin38.40% RSI (14)41.88 Volatility4.60% 7.37%
OptionableYes Debt/Eq0.00 EPS Q/Q15.60% Profit Margin44.30% Rel Volume0.77 Prev Close43.90
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 AMC Payout0.00% Avg Volume496.36K Price43.89
Recom2.60 SMA200.64% SMA50-19.54% SMA200-25.12% Volume380,591 Change-0.02%
Dec-17-18Reiterated Chardan Capital Markets Buy $127.50
Nov-08-18Reiterated BofA/Merrill Neutral $76 → $84
Aug-08-18Reiterated Chardan Capital Markets Buy $130 → $127.50
Jul-23-18Downgrade BofA/Merrill Buy → Neutral
Jul-10-18Reiterated Chardan Capital Markets Buy $90 → $130
May-09-18Reiterated Barclays Overweight $38 → $48
Apr-09-18Reiterated Chardan Capital Markets Buy $85 → $90
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Feb-13-18Initiated Mizuho Neutral $28
Nov-09-17Resumed Morgan Stanley Overweight $34
Nov-09-17Reiterated Chardan Capital Markets Buy $75 → $85
Oct-12-17Initiated Raymond James Outperform $39
Aug-17-17Initiated Evercore ISI Outperform $25
Aug-09-17Reiterated Chardan Capital Markets Buy $50 → $55
Apr-11-17Reiterated Chardan Capital Markets Buy $35 → $50
Oct-20-15Initiated Chardan Capital Markets Buy $33
Oct-13-15Initiated Morgan Stanley Overweight
Oct-12-15Initiated Piper Jaffray Overweight $36
Oct-12-15Initiated BofA/Merrill Buy $29
Jan-04-19 07:00AM  REGENXBIO to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire +10.95%
Jan-03-19 04:05PM  REGENXBIO Reports Continued Progress Across Programs in Year-End 2018 Corporate Update PR Newswire -5.79%
Dec-12-18 02:58AM  Is Regenxbio Inc (RGNX) A Good Stock To Buy? Insider Monkey -6.40%
Dec-04-18 01:58PM  This Rockville biotech is getting some help from Maryland, MoCo for its new HQ American City Business Journals -9.59%
Nov-26-18 08:36AM  Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector Business Wire
08:36AM  REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector PR Newswire
Nov-16-18 01:32AM  DBV Technologies Appoints Daniel Tassé as Chief Executive Officer GlobeNewswire
Nov-14-18 07:00AM  FDA Grants Orphan Drug Designation To RGX-181 Gene Therapy For The Treatment Of CLN2 Form Of Batten Disease PR Newswire -5.89%
Nov-13-18 09:21PM  Edited Transcript of RGNX earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-12-18 09:00AM  Consolidated Research: 2018 Summary Expectations for Murphy Oil, REGENXBIO, CRA International,Inc, Carriage Services, CONMED, and BioDelivery Sciences International Fundamental Analysis, Key Performance Indications GlobeNewswire -5.50%
Nov-07-18 05:52PM  Regenxbio: 3Q Earnings Snapshot Associated Press +5.91%
04:45PM  This Rockville biotech is expanding to a new HQ. Here are the details. American City Business Journals
04:05PM  REGENXBIO Reports Third Quarter 2018 Financial and Operating Results and Announces Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II PR Newswire
04:05PM  Alexandria Real Estate Equities, Inc. Announces Development of New Build-to-Suit at the Alexandria Life Science and Translational Research Center at 9800 Medical Center Drive with Signing of 15-Year, 132,000 RSF Lease for REGENXBIO's New HQ and R&D Facility PR Newswire
Nov-06-18 07:00AM  REGENXBIO to Present at Upcoming Investor Conferences PR Newswire
Nov-05-18 07:00AM  REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector PR Newswire
Oct-31-18 04:05PM  REGENXBIO to Host Conference Call on November 7 to Discuss Third Quarter 2018 Financial Results and Recent Operational Highlights PR Newswire +7.60%
Oct-29-18 09:30AM  ANIK vs. RGNX: Which Stock Should Value Investors Buy Now? Zacks
Oct-26-18 06:10PM  REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting PR Newswire
Oct-22-18 07:00AM  REGENXBIO Announces Exclusive Worldwide License with Ultragenyx for the Treatment of CDKL5 Deficiency Disorder Using NAV Vectors PR Newswire
Oct-18-18 09:20AM  Detailed Research: Economic Perspectives on Control4, REGENXBIO, Ferro, Kadmon, Hemispherx BioPharma, and Murphy Oil What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-04-18 07:00AM  REGENXBIO Announces Completion of Dosing of Fourth Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD PR Newswire
Oct-02-18 04:05PM  REGENXBIO to Present at the Chardan 2nd Annual Genetic Medicines Conference PR Newswire -7.65%
Sep-30-18 03:15PM  Gene Therapy Could Be a Boon for This Biotech Motley Fool
Sep-28-18 11:33AM  Healthcare: 2 Hot Biotech Stocks on Our Radar Motley Fool
Sep-21-18 03:44PM  Taking Profits Early Paid Off In This Biotech Stock Investor's Business Daily
Sep-20-18 11:27AM  Why Amicus Therapeutics Is Up 10% Today Motley Fool
08:35AM  Implied Volatility Surging for REGENXBIO (RGNX) Stock Options Zacks
Sep-14-18 04:23PM  Small Caps Lead Quiet Session; Nasdaq, S&P 500 Mostly Flat; Adobe Jumps Investor's Business Daily +10.33%
Sep-12-18 12:46PM  Is REGENXBIO Incs (NASDAQ:RGNX) ROE Of 24.6% Sustainable? Simply Wall St.
Sep-06-18 04:05PM  REGENXBIO to Present at Upcoming Investor Conferences PR Newswire
Aug-31-18 08:00AM  Todays Research Reports on Stocks to Watch: INSYS Therapeutics and REGENXBIO ACCESSWIRE
Aug-30-18 07:00AM  REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease PR Newswire +10.18%
Aug-27-18 08:15AM  New Research: Key Drivers of Growth for REGENXBIO, Syndax Pharmaceuticals, Rowan Companies, CTS, Basic Energy Services, and Impinj Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-22-18 11:50PM  Edited Transcript of RGNX earnings conference call or presentation 8-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-14-18 04:01PM  REGENXBIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Aug-10-18 07:30AM  REGENXBIO Announces Pricing Of Public Offering Of Common Stock PR Newswire
Aug-09-18 08:39AM  The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings Benzinga -5.46%
Aug-08-18 04:05PM  REGENXBIO Announces Proposed Public Offering Of Common Stock PR Newswire
08:57AM  Regenxbio: 2Q Earnings Snapshot Associated Press
07:30AM  REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemia PR Newswire
06:00AM  REGENXBIO, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-18 05:43PM  REGENXBIO to Host Conference Call and Webcast on August 8 to Discuss Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemia PR Newswire
Aug-06-18 09:30AM  ALXN vs. RGNX: Which Stock Is the Better Value Option? Zacks
Aug-01-18 07:00AM  REGENXBIO to Host Conference Call on August 8 to Discuss Second Quarter 2018 Financial Results and Recent Operational Highlights PR Newswire
Jul-19-18 09:50AM  ALXN or RGNX: Which Is the Better Value Stock Right Now? Zacks
09:45AM  ALXN vs. RGNX: Which Stock Is the Better Value Option? Zacks
07:50AM  10 winners, 10 losers in this years breakout small-cap stock sector MarketWatch
Jul-16-18 08:20AM  Today's Research Reports on Trending Tickers: REGENXBIO and Xencor ACCESSWIRE
Jul-13-18 08:15AM  Better Know Biotech: Regenxbio Inc. Motley Fool
Jul-06-18 08:01PM  3 Top Biotech Stocks to Buy in July Motley Fool
Jul-05-18 07:35AM  Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities ACCESSWIRE
Jul-04-18 08:00AM  Today's Research Reports on Trending Tickers: Tesaro and REGENXBIO ACCESSWIRE
Jul-03-18 09:30AM  3 Best Gene Therapy Stocks of 2018 (So Far) Motley Fool
Jun-29-18 11:40AM  5 Top Performing Stocks of the Best ETF of 1H2018 Zacks
Jun-26-18 09:30AM  ALXN vs. RGNX: Which Stock Should Value Investors Buy Now? Zacks
Jun-25-18 08:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within Immune Pharmaceuticals, Wells Fargo, Anadarko Petroleum, CTS, REGENXBIO, and TripAdvisor New Research Emphasizes Economic Growth GlobeNewswire
Jun-20-18 08:44AM  REGENXBIO (RGNX) in Focus: Stock Moves 6.2% Higher Zacks +10.32%
Jun-13-18 07:48AM  Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111 Benzinga
Jun-12-18 05:36PM  REGENXBIO Receives FDA Fast Track Designation for RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I PR Newswire
Jun-11-18 04:05PM  REGENXBIO Receives $100 Million Accelerated License Payment Due to Acquisition of AveXis by Novartis PR Newswire
Jun-05-18 10:50AM  Why REGENXBIO Inc (NASDAQ:RGNX) Delivered An Inferior ROE Compared To The Industry Simply Wall St. +8.99%
08:05AM  Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index Benzinga
Jun-04-18 06:03PM  Netflix Set to Join S&P 100; Twitter to Join S&P 500; REGENXBIO to Join S&P SmallCap 600 PR Newswire -6.80%
May-29-18 04:05PM  Alexandra Glucksmann Joins REGENXBIO Board of Directors PR Newswire
May-15-18 04:12PM  Edited Transcript of RGNX earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
07:30AM  REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation PR Newswire
May-09-18 04:05PM  REGENXBIO to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference PR Newswire +13.49%
05:08AM  Regenxbio: 1Q Earnings Snapshot Associated Press
May-08-18 04:05PM  REGENXBIO Reports First Quarter 2018 Financial Results and Recent Operational Highlights PR Newswire
May-04-18 07:05AM  Blog Exposure - FDA Granted Fast Track Designation for REGENXBIO's RGX-121 Gene Therapy for Mucopolysaccharidosis Type II ACCESSWIRE
May-02-18 07:00AM  REGENXBIO Receives FDA Fast Track Designation for RGX-121 Gene Therapy for the Treatment of Mucopolysaccharidosis Type II PR Newswire
May-01-18 04:05PM  REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2018 Financial Results and Recent Operational Highlights PR Newswire
Apr-11-18 01:46PM  Harry Boxers five biotech stocks to watch MarketWatch -6.42%
Apr-09-18 05:06PM  What Happened in the Stock Market Today Motley Fool +15.63%
03:51PM  Benzinga's Top Analyst Calls From April 9, 2018 Benzinga
01:36PM  Analyst: AveXis M&A Could Support Interest In Regenxbio Benzinga
12:21PM  How a Rockville company benefits from Novartis' $8.7B purchase of a Chicago biotech American City Business Journals
Mar-22-18 08:00AM  Consolidated Research: 2018 Summary Expectations for REGENXBIO, WD-40, Chesapeake Utilities, Astronics, Park-Ohio, and Cass Information Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-07-18 08:16PM  Edited Transcript of RGNX earnings conference call or presentation 6-Mar-18 9:30pm GMT Thomson Reuters StreetEvents +26.90%
04:05PM  REGENXBIO to Participate in Upcoming Investor Conferences GlobeNewswire
Mar-06-18 05:21PM  Regenxbio reports 4Q loss Associated Press
04:01PM  REGENXBIO Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights GlobeNewswire
12:00PM  REGENXBIO, Inc. to Host Earnings Call ACCESSWIRE
08:57AM  Regenxbio Q4 Earnings Outlook Benzinga
Feb-27-18 04:05PM  REGENXBIO to Host Conference Call on March 6 to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights GlobeNewswire
Feb-12-18 02:56PM  Regenxbio Inc (NASDAQ:RGNX): Financial Strength Analysis Simply Wall St.
Feb-08-18 04:05PM  REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD GlobeNewswire
Feb-07-18 04:05PM  REGENXBIO to Participate in Upcoming Investor Conferences GlobeNewswire
Feb-06-18 10:22AM  See the D.C.-area stocks hit hardest in the last week American City Business Journals
Jan-23-18 04:10PM  REGENXBIO Enhances Gene Therapy Manufacturing Capabilities by Entering into Strategic Partnership with FUJIFILM Diosynth Biotechnologies GlobeNewswire +8.58%
Jan-19-18 07:50AM  Consolidated Research: 2018 Summary Expectations for REGENXBIO, Rexahn Pharmaceuticals, QuinStreet, NewMarket, Stock Yards, and United States Lime & Minerals Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-11-18 03:00AM  Stocks With Rising Relative Price Strength: Regenxbio Investor's Business Daily +6.79%
Jan-08-18 09:31AM  [$$] Gene-Therapy Update: Mixed Results Don't Dim Hopes Barrons.com
08:00AM  REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy GlobeNewswire
Jan-05-18 12:59PM  Here's Why Regenxbio Dropped as Much as 17.6% Today Motley Fool -20.88%
Jan-04-18 04:05PM  REGENXBIO Provides Year-End 2017 Corporate Update GlobeNewswire
Jan-02-18 12:01PM  Edited Transcript of RGNX earnings conference call or presentation 8-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Dec-28-17 12:39PM  ETFs with exposure to REGENXBIO, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:53AM  REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Christmas Patrick J.SVP, General CounselDec 18Option Exercise12.105,00060,5007,669Dec 20 04:27 PM
Christmas Patrick J.SVP, General CounselDec 18Sale47.545,000237,6982,669Dec 20 04:27 PM
Vasista VittalChief Financial OfficerDec 17Sale46.357,500347,650122,283Dec 19 04:32 PM
Mills Kenneth T.President and CEODec 17Sale46.7315,000700,927216,000Dec 19 04:20 PM
Yoo StephenChief Medical OfficerDec 03Option Exercise0.8520,41417,35220,414Dec 06 04:22 PM
Yoo StephenChief Medical OfficerDec 03Sale60.1320,4141,227,4120Dec 06 04:22 PM
Mills Kenneth T.President and CEODec 03Sale60.4020,0001,208,087231,000Dec 06 04:19 PM
Danos OlivierChief Scientific OfficerNov 30Option Exercise20.351,50030,5251,500Dec 04 04:19 PM
BESHAR LUKE MDirectorNov 29Option Exercise3.7612,78448,06812,784Dec 03 04:19 PM
BESHAR LUKE MDirectorNov 29Sale65.0012,784830,9600Dec 03 04:19 PM
BESHAR LUKE MDirectorNov 27Option Exercise18.4718,786346,90818,786Nov 28 04:20 PM
BESHAR LUKE MDirectorNov 27Sale65.0318,7861,221,6540Nov 28 04:20 PM
BESHAR LUKE MDirectorNov 26Option Exercise49.451,72185,1031,721Nov 28 04:20 PM
BESHAR LUKE MDirectorNov 26Sale65.001,721111,8650Nov 28 04:20 PM
Mills Kenneth T.President and CEONov 26Sale64.1720,0001,283,355251,000Nov 28 04:18 PM
Mills Kenneth T.President and CEONov 21Sale61.4415,000921,660271,000Nov 26 04:17 PM
BESHAR LUKE MDirectorNov 20Option Exercise9.0721,176191,96321,176Nov 21 04:26 PM
BESHAR LUKE MDirectorNov 20Sale60.3821,1761,278,6070Nov 21 04:26 PM
BESHAR LUKE MDirectorNov 19Option Exercise23.7812,116288,13812,116Nov 21 04:26 PM
BESHAR LUKE MDirectorNov 19Sale60.5512,116733,6020Nov 21 04:26 PM
Simpson CurranSVP, Technical OperationsNov 16Option Exercise22.0032,882723,40472,382Nov 20 04:19 PM
Simpson CurranSVP, Technical OperationsNov 16Sale63.7632,8822,096,41939,500Nov 20 04:19 PM
Vasista VittalChief Financial OfficerNov 15Sale60.297,500452,206129,783Nov 19 04:16 PM
Christmas Patrick J.SVP, General CounselNov 07Sale72.0615,0001,080,9002,669Nov 09 04:20 PM
Yoo StephenChief Medical OfficerNov 05Option Exercise0.8520,41417,35220,414Nov 07 06:02 PM
Yoo StephenChief Medical OfficerNov 05Sale68.2820,4141,393,9330Nov 07 06:02 PM
Mills Kenneth T.President and CEONov 05Sale68.2520,0001,364,902306,000Nov 07 06:00 PM
Vasista VittalChief Financial OfficerNov 02Option Exercise15.5753,741837,009191,024Nov 05 04:20 PM
Vasista VittalChief Financial OfficerNov 02Sale70.2653,7413,775,843137,283Nov 05 04:20 PM
Vasista VittalChief Financial OfficerNov 01Option Exercise8.3719,677164,654156,960Nov 05 04:20 PM
Vasista VittalChief Financial OfficerNov 01Sale70.0419,6771,378,177137,283Nov 05 04:20 PM
Yoo StephenChief Medical OfficerOct 29Option Exercise0.8520,41417,35220,414Oct 31 04:22 PM
Yoo StephenChief Medical OfficerOct 29Sale62.3720,4141,273,2120Oct 31 04:22 PM
Christmas Patrick J.SVP, General CounselOct 18Option Exercise12.105,00060,50022,669Oct 22 04:16 PM
Christmas Patrick J.SVP, General CounselOct 18Sale61.785,000308,89017,669Oct 22 04:16 PM
Yoo StephenChief Medical OfficerOct 16Option Exercise0.8510,4148,85210,414Oct 17 04:29 PM
Simpson CurranSVP, Technical OperationsOct 16Option Exercise21.0962,3091,314,22386,017Oct 18 04:24 PM
Simpson CurranSVP, Technical OperationsOct 16Sale60.8562,3093,791,50339,500Oct 18 04:24 PM
Yoo StephenChief Medical OfficerOct 16Sale61.1810,414637,1290Oct 17 04:29 PM
Yoo StephenChief Medical OfficerOct 15Option Exercise0.8510,0008,50010,000Oct 17 04:29 PM
Vasista VittalChief Financial OfficerOct 15Sale59.377,500445,275137,283Oct 17 04:24 PM
Mills Kenneth T.President and CEOOct 15Sale59.357,510445,745326,000Oct 17 04:17 PM
Yoo StephenChief Medical OfficerOct 15Sale59.3410,000593,4120Oct 17 04:29 PM
Danos OlivierChief Scientific OfficerOct 08Option Exercise20.3520,000407,00020,000Oct 10 04:20 PM
Danos OlivierChief Scientific OfficerOct 08Sale63.8020,0001,275,9140Oct 10 04:20 PM
Vasista VittalChief Financial OfficerSep 17Option Exercise0.8530,00025,500144,783Sep 19 04:26 PM
Vasista VittalChief Financial OfficerSep 17Sale74.867,500561,472114,783Sep 19 04:26 PM
Mills Kenneth T.President and CEOSep 17Sale74.917,510562,564333,510Sep 19 04:24 PM
Mills Kenneth T.President and CEOAug 27Option Exercise0.85145,000123,250348,530Aug 29 04:20 PM
Mills Kenneth T.President and CEOAug 27Sale66.467,510499,118341,020Aug 29 04:20 PM
Christmas Patrick J.SVP, General CounselAug 20Option Exercise12.105,00060,50022,669Aug 22 04:15 PM
Christmas Patrick J.SVP, General CounselAug 20Sale65.965,000329,80617,669Aug 22 04:15 PM
Vasista VittalChief Financial OfficerAug 15Sale65.437,500490,710122,283Aug 17 04:17 PM
Vasista VittalChief Financial OfficerJul 16Sale75.547,500566,522129,783Jul 18 04:16 PM
Mills Kenneth T.President and CEOJun 20Sale66.205,000331,018203,530Jun 22 04:15 PM
Christmas Patrick J.SVP, General CounselJun 19Option Exercise12.101,52818,48917,669Jun 20 04:12 PM
Christmas Patrick J.SVP, General CounselJun 18Option Exercise12.105,00060,50021,141Jun 20 04:12 PM
Christmas Patrick J.SVP, General CounselJun 18Sale56.785,000283,88616,141Jun 20 04:12 PM
Vasista VittalChief Financial OfficerJun 15Sale56.617,500424,540137,283Jun 19 04:17 PM
HAYDEN DONALD J JRDirectorJun 05Option Exercise0.8514,90012,66514,900Jun 05 05:40 PM
HAYDEN DONALD J JRDirectorJun 05Sale55.0114,900819,6490Jun 05 05:40 PM
HAYDEN DONALD J JRDirectorJun 01Option Exercise0.8510085100Jun 05 05:40 PM
HAYDEN DONALD J JRDirectorJun 01Sale55.001005,5000Jun 05 05:40 PM
Mills Kenneth T.President and CEOMay 21Sale47.0510,000470,540208,530May 23 04:16 PM
HAYDEN DONALD J JRDirectorMay 15Option Exercise0.859,8478,3709,847May 16 04:15 PM
Vasista VittalChief Financial OfficerMay 15Sale50.107,500375,721144,783May 16 04:20 PM
HAYDEN DONALD J JRDirectorMay 15Sale50.069,847492,9410May 16 04:15 PM
HAYDEN DONALD J JRDirectorMay 14Option Exercise0.855,1534,3805,153May 16 04:15 PM
HAYDEN DONALD J JRDirectorMay 14Sale50.045,153257,8560May 16 04:15 PM
Christmas Patrick J.SVP, General CounselMay 10Option Exercise12.1015,000181,50016,141May 11 04:18 PM
HAYDEN DONALD J JRDirectorMay 09Option Exercise0.8515,00012,75015,000May 11 04:17 PM
Christmas Patrick J.SVP, General CounselMay 09Option Exercise12.1015,000181,50016,141May 11 04:18 PM
Christmas Patrick J.SVP, General CounselMay 09Sale43.3315,000650,0001,141May 11 04:18 PM
HAYDEN DONALD J JRDirectorMay 09Sale45.0015,000675,0000May 11 04:17 PM
Mills Kenneth T.President and CEOApr 20Sale39.5210,000395,205218,530Apr 24 04:16 PM
Vasista VittalChief Financial OfficerApr 16Sale37.565,000187,797152,283Apr 18 04:17 PM
Christmas Patrick J.SVP, General CounselApr 11Option Exercise12.1010,000121,00011,141Apr 13 04:17 PM
Christmas Patrick J.SVP, General CounselApr 11Sale39.0010,000390,0001,141Apr 13 04:17 PM
Christmas Patrick J.SVP, General CounselApr 09Option Exercise12.1010,000121,00011,141Apr 11 04:19 PM
Christmas Patrick J.SVP, General CounselApr 09Sale34.0010,000340,0001,141Apr 11 04:19 PM
Vasista VittalChief Financial OfficerMar 26Sale30.005,000150,000157,283Mar 28 04:20 PM
Mills Kenneth T.President and CEOMar 20Sale29.5510,000295,500228,530Mar 22 04:17 PM
Simpson CurranSVP, Technical OperationsMar 13Option Exercise22.0025,000550,00064,500Mar 15 04:16 PM
Simpson CurranSVP, Technical OperationsMar 13Sale33.0025,000825,00039,500Mar 15 04:16 PM
Vasista VittalChief Financial OfficerMar 06Option Exercise0.8560,00051,000162,283Mar 08 04:23 PM
Vasista VittalChief Financial OfficerFeb 28Sale30.005,000150,000102,283Mar 02 04:16 PM
Mills Kenneth T.President and CEOFeb 20Sale26.5610,000265,600238,530Feb 22 05:14 PM
Mills Kenneth T.President and CEOJan 22Sale27.3310,000273,300248,530Jan 24 04:17 PM